Table 3.
Concentration of sVCAM-1 in the serum of women with breast cancer in relation to age, clinical stage of disease, lymph node status, tumour size, and histological malignancy grade
| Patient characteristic | mean sVCAM-1 concentration [ng/ml] | sVCAM-1 median sVCAM-1 concentration [ng/ml] | sVCAM-1 concentration range [ng/ml] |
|---|---|---|---|
| Control group n = 40 | 274.5 ±41.2 | 280.8 | 201.3–344.4 |
| Breast cancer patients n = 103 | 648.0* ±312.6 | 559.9* | 240.0–1516.3 |
| Age Pre-menopausal Post-menopausal |
635.4* ±303.0 653.5* ±318.6 |
548.0* 585.2* |
245.0–1420.1 254.2–1516.3 |
| Stage of clinical disease advancement according to TNM I (n = 47) II (n = 38) III (n = 18) |
439.6* ±176.7 730.0*& ±236.3 782.6*&# ±335 |
387.8* 704.9*& 754.5*&# |
245.0–1047.0 318.4–1420.3 383.4–1516.3 |
| Axillary lymph node status pN0 (n = 51) pN1 (n = 52) |
510.9* ±216.2 782.6*▼ ±335.1 |
421.3* 763.6*▼ |
245.0–992.1 297.3–1516.3 |
| Tumour size pT < 20 mm (n = 54) pT ≥ 20 < 50 mm (n = 40) pT ≥ 50 mm (n = 9) |
1257.3* ±545.3 1975.1*▼ ±631.8 2846.6*■ ±624 |
1154.0* 1988.0*◆ 3147.7*◆▼ |
595.9–2944.0 688.0–3425.9 1595.2–3492.1 |
| Histological grade of malignancy G1 (n = 11) G2 (n = 50) G3 (n = 42) |
451.1* ±218.6 595.1*△ ±273.0 762.7*△❑ ±339.2 |
332.4* 506.1*△ 739.6*△❑ |
286.7–954.5 245.0–1420.1 292.7–1516.3 |
n – number of tested individuals
Statistically significant difference for sVCAM-1 in comparison to the control group p < 0.05
Statistically significant difference for sVCAM-1 in comparison to the women in stage I of clinical disease advancement p < 0.05
Statistically significant difference for sVCAM-1 in comparison to the women in stage II of clinical disease advancement p < 0.05
Statistically significant difference for sVCAM-1 in comparison to the group of women without metastases to the axillary lymph nodes p < 0.05
r statistically significant difference for sVCAM-1 in comparison to the group of women with tumours measuring < 20 mm, p < 0.05
Statistically significant difference for sVCAM-1 in comparison to the group of women with tumours measuring ≥ 20 < 50 mm, p < 0.05
Statistically significant difference for sVCAM-1 in comparison to the women with a G1 histological grade of malignancy, p < 0.05
Statistically significant difference for sVCAM-1 in comparison to the women with a G2 histological grade of malignancy, p < 0.05